Methylxanthines are non-selective antagonists of adenosine receptors and it turns out that one of them, the A2A receptor (A2AR) is highly enriched in striatum (Rosin et al., 1998), i.e., in the main target structure of any pharmacological anti-PD treatment. This evidence concerns the gene ADORA2A and Parkinson disease.